Everest Medicines Limited is a biopharmaceutical company that discovers, develops, manufactures, and commercializes pharmaceutical products to address unmet medical needs. The company integrates licensing, clinical development, and commercialization, focusing on therapeutic areas including autoimmune diseases, ophthalmology, critical care, and cardiovascular, kidney, and metabolic (CKM) diseases. Its commercial portfolio includes Xerava, Nefecon, and Velsipity, which are marketed in Greater China, Singapore, Taiwan, and Korea. Everest Medicines operates a model combining business development collaborations with in-house research and development, leveraging a proprietary mRNA platform to advance pipeline candidates such as mRNA in vivo CAR-T and mRNA cancer vaccines. The company serves patients in Greater China and other emerging Asia Pacific markets while pursuing global expansion.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage everestmedicines.com
Sector Healthcare IR page everestmedicines.com/investors
Tags
biopharmaceuticals, autoimmune diseases, ophthalmology, critical care, cardiovascular diseases, kidney diseases, metabolic diseases, mrna technology, car-t therapy, cancer vaccines, clinical development, commercialization, Xerava, Nefecon, Velsipity, CBC Group
Press page —

Metrics

Valuation  
Market cap HK$ 8.14B
Market cap (USD) $ 1.037B
P/E -128.27
PEG —
P/BV 1.32
P/S 2.87
P/OCF -37.67
P/FCF —
Dividend yield —
Turnover / mcap 1.2%
Returns  
ROE -6.4%
ROI -5.5%
ROIC -5.5%
Profit margin -17.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 5.4%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -20.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 1.707B 706.678M 125.932M 12.792M 54K — —
Net profit -297.766M -1.041B -844.463M -247.283M -1.009B -5.658B —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 34.12 41.85 26.04 9.75 25.08 54.98 —
Price performance 12m -0.17 0.62 1.52 -0.63 -0.51 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Everest Medicines Limited (ticker 1952), listed in Hong Kong.

ETFs Holding Everest Medicines Limited

ETF Weight in ETF Shares Market value As of
DFAE 0.01% 152,500 $ 510.106K Nov 12, 2026
DFEM 0.00% 98,500 $ 329.478K Nov 12, 2026
DFAX 0.00% 104,500 $ 349.548K Nov 12, 2026
AVES 0.00% 4,000 $ 12.982K Nov 16, 2026